Cover Image
市場調查報告書

積極的經皮藥物遞輸

Active Transdermal Drug Delivery to 2018

出版商 Greystone Research Associates 商品編碼 300588
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
積極的經皮藥物遞輸 Active Transdermal Drug Delivery to 2018
出版日期: 2014年05月01日 內容資訊: 英文
簡介

本報告提供積極的經皮藥物遞輸市場相關調查、主要市場區隔、技術、製劑的主要的治療需求的促進要素、設計的課題、產品商業化的市場影響因素、市場現狀及預測、市場參與企業與其經營模式,及經濟、技術、規定因素的影響等相關分析,為您概述為以下內容。

摘要整理

積極的經皮藥物遞輸市場力學

  • 積極的經皮技術概要
  • 經皮給藥的推動市場的要素
  • 賦形劑、滲透催化劑
  • 競爭情形
  • 阻礙成長要素

積極的經皮技術

  • 電流
  • 離子電滲
  • 電穿孔
  • 微穿孔
  • 雷射
  • 機械陣列
  • 高頻
  • 環境熱能
  • 超音波

積極的經皮設計因素

  • 製劑因素
  • 專用遞送(給藥)vs.第三者貼片(修補程式)
  • 用量和比例
  • 生物適合性

商用積極的經皮平台:評估、展望

  • 電穿孔
  • 離子電滲
  • 微穿孔
  • 環境熱能
  • 超音波

積極的經皮給藥:市場分析與預測

  • 麻醉
  • 皮質類固醇
  • 非病毒性遺傳基因遞送
  • 代謝疾病
  • 疼痛管理
  • 物理療法
  • 疫苗

市場因素

  • FDA法規
  • 臨床實驗流程
  • 從處方藥轉換至成藥(Rx-to-OTC)
  • 患者統計的變化

市場參與企業簡介

目錄
Product Code: ATD741R

The administration of therapeutic drugs via e advantages of transdermal drug delivery for improving patient compliance, particularly for the treatment of chronic conditions, are well known. But growth of transdermal delivery has been restricted by the need to limit candidate drugs to molecules small enough to effectively pass through the stratum corneum, a limitation that excludes passive transdermal patches as a viable option for the growing number of protein and peptide therapeutic compounds that will represent an increasing share of future NCEs. New technologies that employ energy or mechanical designs to affect drug transport through the skin are expanding the type and number of drug candidates that are viable for transdermal delivery. Evolving active transdermal systems will be well-positioned to address a significant segment of the large -molecule biological drugs expected to emerge from the convergence of automated discovery and genome mapping. As designs shrink in size and become more patient-friendly, opportunities for active transdermal delivery will increase.

Highlights

  • What are the key segments and technologies that comprise the market for active transdermal drug delivery?
  • What are the major therapeutic demand drivers for active transdermal drug products?
  • What are the design issues and market factors that influence product commercialization?
  • What is the market today and what will it look like in 2018?
  • Who are the companies behind the current generation of active transdermal delivery and what are their business models?
  • What is the role of pharma-device alliances and design partnerships?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Executive Summary

Active Transdermal Drug Delivery Market Dynamics

  • Active Transdermal Technology Overview
  • Market Drivers for Transdermal Delivery
  • Excipients and Penetration Enhancers
  • Competitive Landscape
  • Factors Limiting Growth

Active Transdermal Technologies

  • Electrical Current
  • Iontophoresis
  • Electroporation
  • Microporation
  • Lasers
  • Mechanical Arrays
  • Radio Frequency
  • Thermal/Heat
  • Ultrasound

Active Transdermal Design Factors

  • Drug Formulation Factors
  • Proprietary Delivery vs. 3rd Party Patches
  • Dosing and Rate Factors
  • Biocompatibility

Commercial Active Transdermal Platforms - Assessment & Prospects

  • Electroporation
  • Iontophoresis
  • Microporation
  • Thermal
  • Ultrasound

Active Transdermal Delivery - Market Analysis & Forecasts

  • Anesthesia
  • Corticosteriods
  • Nonviral Gene Delivery
  • Metabolic Diseases
  • Pain Management
  • Physical Medicine
  • Vaccines

Market Factors

  • FDA Regulations
  • Clinical Trial Process
  • Rx-to-OTC Switching
  • Shifting Patient Demographics

Market Participant Profiles

Back to Top